{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:49:32Z","timestamp":1790243372353,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The acid sphingomyelinase (ASM)\/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting the acid sphingomyelinase\/ceramide system (named FIASMA psychotropic medications) against COVID-19. We examined the potential usefulness of FIASMA psychotropic medications in patients with psychiatric disorders hospitalized for severe COVID-19, in an observational multicenter study conducted at Greater Paris University hospitals. Of 545 adult inpatients, 164 (30.1%) received a FIASMA psychotropic medication upon hospital admission for COVID-19. We compared the composite endpoint of intubation or death between patients who received a psychotropic FIASMA medication at baseline and those who did not in time-to-event analyses adjusted for sociodemographic characteristics, psychiatric and other medical comorbidity, and other medications. FIASMA psychotropic medication use at baseline was significantly associated with reduced risk of intubation or death in both crude (HR\u2009=\u20090.42; 95%CI\u2009=\u20090.31\u20130.57;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and primary inverse probability weighting (IPW) (HR\u2009=\u20090.50; 95%CI\u2009=\u20090.37\u20130.67;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) analyses. This association was not specific to one FIASMA psychotropic class or medication. Patients taking a FIASMA antidepressant at baseline had a significantly reduced risk of intubation or death compared with those taking a non-FIASMA antidepressant at baseline in both crude (HR\u2009=\u20090.57; 95%CI\u2009=\u20090.38\u20130.86;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and primary IPW (HR\u2009=\u20090.57; 95%CI\u2009=\u20090.37\u20130.87;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) analyses. These associations remained significant in multiple sensitivity analyses. Our results show the potential importance of the ASM\/ceramide system framework in COVID-19 and support the continuation of FIASMA psychotropic medications in these patients and the need of large- scale clinical trials evaluating FIASMA medications, and particularly FIASMA antidepressants, against COVID-19.\n                  <\/jats:p>","DOI":"10.1038\/s41398-022-01804-5","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T10:02:39Z","timestamp":1646301759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-1349","authenticated-orcid":false,"given":"Nicolas","family":"Hoertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-8641","authenticated-orcid":false,"given":"Marina","family":"S\u00e1nchez-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Gulbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-3987","authenticated-orcid":false,"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carpinteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Abell\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"de la Muela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3358-9005","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Vernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathana\u00ebl","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Neuraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Delcuze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-0147","authenticated-orcid":false,"given":"Jes\u00fas M.","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Cougoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Meneton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-1514","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Limosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of AP-HP\/Universit\u00e9 de Paris\/INSERM COVID-19 research collaboration\/AP-HP COVID CDR Initiative\/\u201cEntrep\u00f4t de Donn\u00e9es de Sant\u00e9\u201d AP-HP Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"1804_CR1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41591-020-1001-6","volume":"26","author":"N Hoertel","year":"2020","unstructured":"Hoertel N, Blachier M, Blanco C, Olfson M, Massetti M, S\u00e1nchez-Rico M, et al. A stochastic agent-based model of the SARS-CoV-2 epidemic in France. Nat Med. 2020;26:1417\u201321.","journal-title":"Nat Med"},{"key":"1804_CR2","doi-asserted-by":"publisher","unstructured":"Hoertel N, Blachier M, Blanco C, Olfson M, Massetti M, Limosin F et al. Facing the COVID-19 epidemic in NYC: a stochastic agent-based model of various intervention strategies. 2020. https:\/\/doi.org\/10.1101\/2020.04.23.20076885.","DOI":"10.1101\/2020.04.23.20076885"},{"key":"1804_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.encep.2020.04.005","volume":"46","author":"A Chevance","year":"2020","unstructured":"Chevance A, Gourion D, Hoertel N, Llorca P-M, Thomas P, Bocher R, et al. Ensuring mental health care during the SARS-CoV-2 epidemic in France: a narrative review. L\u2019Encephale. 2020;46:193\u2013201.","journal-title":"L\u2019Encephale"},{"key":"1804_CR4","doi-asserted-by":"publisher","unstructured":"Hoertel N, Blachier M, S\u00e1nchez-Rico M, Limosin F, Leleu H. Impact of the timing and adherence to face mask use on the course of the COVID-19 epidemic in France. J Travel Med. 2021. https:\/\/doi.org\/10.1093\/jtm\/taab016.","DOI":"10.1093\/jtm\/taab016"},{"key":"1804_CR5","doi-asserted-by":"publisher","unstructured":"Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2021. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6454.","DOI":"10.1001\/jamainternmed.2021.6454"},{"key":"1804_CR6","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, et al. Repurposing antidepressants inhibiting the sphingomyelinase acid\/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry 2021. https:\/\/doi.org\/10.1038\/s41380-021-01254-3.","DOI":"10.1038\/s41380-021-01254-3"},{"key":"1804_CR7","doi-asserted-by":"crossref","first-page":"e2136510","DOI":"10.1001\/jamanetworkopen.2021.36510","volume":"4","author":"N Hoertel","year":"2021","unstructured":"Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4:e2136510.","journal-title":"JAMA Netw Open"},{"key":"1804_CR8","doi-asserted-by":"publisher","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;100142. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100142.","DOI":"10.1016\/j.xcrm.2020.100142"},{"key":"1804_CR9","doi-asserted-by":"publisher","unstructured":"Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase\/ceramide system in COVID-19. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-021-01309-5. 2021.","DOI":"10.1038\/s41380-021-01309-5"},{"key":"1804_CR10","doi-asserted-by":"publisher","unstructured":"Carpinteiro A, Gripp B, Hoffmann M, P\u00f6hlmann S, Hoertel N, Edwards MJ, et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021;100701. https:\/\/doi.org\/10.1016\/j.jbc.2021.100701.","DOI":"10.1016\/j.jbc.2021.100701"},{"key":"1804_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","volume":"26","author":"J Kornhuber","year":"2010","unstructured":"Kornhuber J, Tripal P, Reichel M, M\u00fchle C, Rhein C, Muehlbacher M, et al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26:9\u201320.","journal-title":"Cell Physiol Biochem"},{"key":"1804_CR12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","volume":"9","author":"S Schloer","year":"2020","unstructured":"Schloer S, Brunotte L, Goretzko J, Mecate-Zambrano A, Korthals N, Gerke V, et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9:2245\u201355.","journal-title":"Emerg Microbes Infect"},{"key":"1804_CR13","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1192\/bjo.2021.1053","volume":"8","author":"CL Clelland","year":"2021","unstructured":"Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open. 2021;8:e6.","journal-title":"BJPsych Open"},{"key":"1804_CR14","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3390\/ijms22094794","volume":"22","author":"J Mar\u00edn-Corral","year":"2021","unstructured":"Mar\u00edn-Corral J, Rodr\u00edguez-Morat\u00f3 J, Gomez-Gomez A, Pascual-Guardia S, Mu\u00f1oz-Berm\u00fadez R, Salazar-Degracia A, et al. Metabolic signatures associated with severity in hospitalized COVID-19 patients. IJMS. 2021;22:4794.","journal-title":"IJMS"},{"key":"1804_CR15","doi-asserted-by":"crossref","unstructured":"Khodadoust MM. Ceramide levels and Covid-19 respiratory distress, a causal relationship. Res Square. 2021. https:\/\/assets.researchsquare.com\/files\/rs-443020\/v1_stamped.pdf.","DOI":"10.21203\/rs.3.rs-443020\/v1"},{"key":"1804_CR16","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.3390\/ijms221910198","volume":"22","author":"E Torretta","year":"2021","unstructured":"Torretta E, Garziano M, Poliseno M, Capitanio D, Biasin M, Santantonio TA, et al. Severity of COVID-19 patients predicted by serum sphingolipids signature. IJMS. 2021;22:10198.","journal-title":"IJMS"},{"key":"1804_CR17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0014-5793(04)00033-X","volume":"559","author":"M K\u00f6lzer","year":"2004","unstructured":"K\u00f6lzer M, Werth N, Sandhoff K. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 2004;559:96\u201398.","journal-title":"FEBS Lett"},{"key":"1804_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/bchm3.1994.375.7.447","volume":"375","author":"R Hurwitz","year":"1994","unstructured":"Hurwitz R, Ferlinz K, Sandhoff K. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe-Seyler. 1994;375:447\u201350.","journal-title":"Biol Chem Hoppe-Seyler"},{"key":"1804_CR19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nm.3214","volume":"19","author":"E Gulbins","year":"2013","unstructured":"Gulbins E, Palmada M, Reichel M, L\u00fcth A, B\u00f6hmer C, Amato D, et al. Acid sphingomyelinase\u2013ceramide system mediates effects of antidepressant drugs. Nat Med. 2013;19:934\u20138.","journal-title":"Nat Med"},{"key":"1804_CR20","doi-asserted-by":"crossref","first-page":"e23852","DOI":"10.1371\/journal.pone.0023852","volume":"6","author":"J Kornhuber","year":"2011","unstructured":"Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PloS ONE. 2011;6:e23852.","journal-title":"PloS ONE"},{"key":"1804_CR21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cpt.2317","volume":"110","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, et al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharm Ther. 2021;110:1498\u2013511.","journal-title":"Clin Pharm Ther"},{"key":"1804_CR22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/ph14030226","volume":"14","author":"G Darquennes","year":"2021","unstructured":"Darquennes G, Le Corre P, Le Moine O, Loas G. Association between functional inhibitors of acid sphingomyelinase (Fiasmas) and reduced risk of death in covid-19 patients: a retrospective cohort study. Pharmaceuticals. 2021;14:226.","journal-title":"Pharmaceuticals"},{"key":"1804_CR23","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","volume":"26","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Jannot A-S, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199\u2013212.","journal-title":"Mol Psychiatry"},{"key":"1804_CR24","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.3390\/jcm10245891","volume":"10","author":"M S\u00e1nchez-Rico","year":"2021","unstructured":"S\u00e1nchez-Rico M, Limosin F, Vernet R, Beeker N, Neuraz A, Blanco C, et al. Hydroxyzine use and mortality in patients hospitalized for COVID-19: a multicenter observational study. JCM. 2021;10:5891.","journal-title":"JCM"},{"key":"1804_CR25","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Herrera-Morueco JJ, de la Muela P, Gulbins E, Kornhuber J, et al. Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients. Mol Psychiatry. 2021. https:\/\/doi.org\/10.1038\/s41380-021-01393-7.","DOI":"10.1038\/s41380-021-01393-7"},{"key":"1804_CR26","doi-asserted-by":"publisher","first-page":"e2133090","DOI":"10.1001\/jamanetworkopen.2021.33090","volume":"4","author":"T Oskotsky","year":"2021","unstructured":"Oskotsky T, Maric I, Tang A, Oskotsky B, Wong R, Aghaeepour N, et al. Mortality risk among patients with COVID-19 prescribed SSRI antidepressants. JAMA Netw Open. 2021;4:e2133090. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33090.","journal-title":"JAMA Netw Open"},{"key":"1804_CR27","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292\u20132300.","journal-title":"JAMA"},{"key":"1804_CR28","doi-asserted-by":"crossref","first-page":"ofab050","DOI":"10.1093\/ofid\/ofab050","volume":"8","author":"D Seftel","year":"2021","unstructured":"Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8:ofab050.","journal-title":"Open Forum Infect Dis"},{"key":"1804_CR29","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","volume":"10","author":"G Reis","year":"2022","unstructured":"Reis G, dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42\u2013e51. https:\/\/doi.org\/10.1016\/S2214-109X(21)00448-4.","journal-title":"Lancet Glob Health"},{"key":"1804_CR30","doi-asserted-by":"publisher","unstructured":"Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021. https:\/\/doi.org\/10.1111\/bcp.15126.","DOI":"10.1111\/bcp.15126"},{"key":"1804_CR31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1176\/appi.focus.16407","volume":"16","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus 2018;16:420\u20139.","journal-title":"Focus"},{"key":"1804_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31\u201341.","journal-title":"Lancet"},{"key":"1804_CR33","doi-asserted-by":"publisher","unstructured":"Hoertel N, Rotenberg L, Blanco C, Camus V, Dubertret C, Charlot V, et al. A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study. Soc Psychiatry Psychiatr Epidemiol. 2020. https:\/\/doi.org\/10.1007\/s00127-020-01880-2.","DOI":"10.1007\/s00127-020-01880-2"},{"key":"1804_CR34","doi-asserted-by":"crossref","first-page":"e0247122","DOI":"10.1371\/journal.pone.0247122","volume":"16","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Jannot A-S, Neuraz A, Blanco C, et al. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS ONE. 2021;16:e0247122.","journal-title":"PLoS ONE"},{"key":"1804_CR35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40261-021-01001-0","volume":"41","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Jannot A-S, Neuraz A, Blanco C, et al. Observational study of chlorpromazine in hospitalized patients with COVID-19. Clin Drug Investig. 2021;41:221\u201333.","journal-title":"Clin Drug Investig"},{"key":"1804_CR36","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/bcp.14784","volume":"87","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Neuraz A, Alvarado JM, et al. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study. Br J Clin Pharm. 2021;87:3766\u201375.","journal-title":"Br J Clin Pharm"},{"key":"1804_CR37","doi-asserted-by":"crossref","first-page":"e2023282","DOI":"10.1001\/jamanetworkopen.2020.23282","volume":"3","author":"L Li","year":"2020","unstructured":"Li L, Li F, Fortunati F, Krystal JH. Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection. JAMA Netw open. 2020;3:e2023282\u2013e2023282.","journal-title":"JAMA Netw open"},{"key":"1804_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","volume":"26","author":"QQ Wang","year":"2021","unstructured":"Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26:30\u201339. https:\/\/doi.org\/10.1038\/s41380-020-00880-7.","journal-title":"Mol Psychiatry"},{"key":"1804_CR39","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Statement on the management at home or in a care facility of suspected or confirmed Covid-19 patients. 2020.https:\/\/www.hcsp.fr (accessed 5 May 2021)."},{"key":"1804_CR40","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrobial Agents. 2020;55:105954.","journal-title":"Int J Antimicrobial Agents"},{"key":"1804_CR41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jmv.25819","volume":"92","author":"FA Lagunas-Rangel","year":"2020","unstructured":"Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol. 2020;92:1733\u20134.","journal-title":"J Med Virol"},{"key":"1804_CR42","doi-asserted-by":"crossref","unstructured":"Terry M Therneau, Patricia M Grambsch. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"1804_CR43","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl J Med. 2020;382:2411\u20138.","journal-title":"N. Engl J Med"},{"key":"1804_CR44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n M\u00c1, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550\u201360.","journal-title":"Epidemiology"},{"key":"1804_CR45","doi-asserted-by":"crossref","unstructured":"Venables WN, Ripley BD. Modern Applied Statistics with S. Fourth. Springer: New York, 2002. http:\/\/www.stats.ox.ac.uk\/pub\/MASS4\/.","DOI":"10.1007\/978-0-387-21706-2"},{"key":"1804_CR46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2307\/3314608","volume":"9","author":"B Efron","year":"1981","unstructured":"Efron B. Nonparametric standard errors and confidence intervals. Can J Stat. 1981;9:139\u201358.","journal-title":"Can J Stat"},{"key":"1804_CR47","unstructured":"Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using \u2018ggplot2\u2019. 2020 https:\/\/CRAN.R-project.org\/package=survminer."},{"key":"1804_CR48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1198\/106186006X137047","volume":"15","author":"BB Hansen","year":"2006","unstructured":"Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graph Stat. 2006;15:609\u201327.","journal-title":"J Comput Graph Stat"},{"key":"1804_CR49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u201326.","journal-title":"Biometrika"},{"key":"1804_CR50","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"1804_CR51","doi-asserted-by":"publisher","first-page":"755600.","DOI":"10.3389\/fphar.2021.755600","volume":"12","author":"MS Fred","year":"2022","unstructured":"Fred MS, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, et al. Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. Front Pharmacol. 2022;12:755600. https:\/\/doi.org\/10.3389\/fphar.2021.755600.","journal-title":"Front Pharmacol"},{"key":"1804_CR52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85049-0","volume":"11","author":"M Zimniak","year":"2021","unstructured":"Zimniak M, Kirschner L, Hilpert H, Geiger N, Danov O, Oberwinkler H, et al. The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11:5890.","journal-title":"Sci Rep"},{"key":"1804_CR53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/microorganisms9020339","volume":"9","author":"A Dechaumes","year":"2021","unstructured":"Dechaumes A, Nekoua MP, Belouzard S, Sane F, Engelmann I, Dubuisson J, et al. Fluoxetine can inhibit SARS-CoV-2 in vitro. Microorganisms. 2021;9:339.","journal-title":"Microorganisms"},{"key":"1804_CR54","doi-asserted-by":"crossref","unstructured":"Schloer S, Brunotte L, Mecate\u2010Zambrano A, Zheng S, Tang J, Ludwig S et al. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS\u2010CoV\u20102 infection in vitro. Br J Pharmacol. 2021; bph.15418.","DOI":"10.1101\/2020.10.16.342410"},{"key":"1804_CR55","doi-asserted-by":"publisher","unstructured":"N\u00e9meth Z, Sz\u0171cs A, Vitrai J, Juh\u00e1sz D, N\u00e9meth JP, Holl\u00f3 A. Fluoxetine might improve survival of patients with COVID-19 pneumonia: a retrospective case-control study. SSRN J. 2021. https:\/\/doi.org\/10.2139\/ssrn.3896539.","DOI":"10.2139\/ssrn.3896539"},{"key":"1804_CR56","doi-asserted-by":"crossref","first-page":"101989","DOI":"10.1016\/j.pupt.2021.101989","volume":"67","author":"JI Mor\u00e1n Blanco","year":"2021","unstructured":"Mor\u00e1n Blanco JI, Alvarenga Bonilla JA, Homma S, Suzuki K, Fremont-Smith P, Villar G\u00f3mez de las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care \u2013 A retrospective observational study in elderly patients. Pulm Pharmacol Therapeutics. 2021;67:101989.","journal-title":"Pulm Pharmacol Therapeutics"},{"key":"1804_CR57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/acps.13304","volume":"143","author":"C Diez\u2010Quevedo","year":"2021","unstructured":"Diez\u2010Quevedo C, Iglesias\u2010Gonz\u00e1lez M, Giralt\u2010L\u00f3pez M, Rangil T, Sanagustin D, Moreira M, et al. Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID\u201019 Spanish inpatients. Acta Psychiatr Scand. 2021;143:526\u201334.","journal-title":"Acta Psychiatr Scand"},{"key":"1804_CR58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","volume":"727","author":"T Ishima","year":"2014","unstructured":"Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167\u201373.","journal-title":"Eur J Pharmacol"},{"key":"1804_CR59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","volume":"62","author":"M Ishikawa","year":"2007","unstructured":"Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C] SA4503. Biol Psychiatry. 2007;62:878\u201383.","journal-title":"Biol Psychiatry"},{"key":"1804_CR60","first-page":"1","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov. 2020;6:1\u201318.","journal-title":"Cell Discov"},{"key":"1804_CR61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1465-9921-8-35","volume":"8","author":"C Roumestan","year":"2007","unstructured":"Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, et al. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res. 2007;8:35.","journal-title":"Respir Res"},{"key":"1804_CR62","first-page":"4195","volume":"55","author":"CA K\u00f6hler","year":"2018","unstructured":"K\u00f6hler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018;55:4195\u2013206.","journal-title":"Mol Neurobiol"},{"key":"1804_CR63","doi-asserted-by":"crossref","first-page":"eaau5266","DOI":"10.1126\/scitranslmed.aau5266","volume":"11","author":"DA Rosen","year":"2019","unstructured":"Rosen DA, Seki SM, Fern\u00e1ndez-Casta\u00f1eda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor\u2013IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266.","journal-title":"Sci Transl Med"},{"key":"1804_CR64","doi-asserted-by":"crossref","first-page":"652688","DOI":"10.3389\/fphar.2021.652688","volume":"12","author":"VP Sukhatme","year":"2021","unstructured":"Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharm. 2021;12:652688.","journal-title":"Front Pharm"},{"key":"1804_CR65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jphs.2014.11.010","volume":"127","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015;127:6\u20139.","journal-title":"J Pharmacol Sci"},{"key":"1804_CR66","doi-asserted-by":"crossref","unstructured":"Krutetskaya Z, Melnitskaya A, Antonov V, Nozdrachev A. Sigma-1 receptor antagonists haloperidol and chlorpromazine modulate the effect of glutoxim on NA+ transport in frog skin. In: Doklady Biochemistry and Biophysics. Springer, 2019, pp 63\u201365.","DOI":"10.1134\/S1607672919010186"},{"key":"1804_CR67","doi-asserted-by":"crossref","first-page":"582310","DOI":"10.3389\/fphar.2020.582310","volume":"11","author":"JM Vela","year":"2020","unstructured":"Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharm. 2020;11:582310.","journal-title":"Front Pharm"},{"key":"1804_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regeneration. 2020;40:1\u20137.","journal-title":"Inflamm Regeneration"},{"key":"1804_CR69","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of theCytokine Storm\u2019in COVID-19. J Infect. 2020;80:607\u201313.","journal-title":"J Infect"},{"key":"1804_CR70","doi-asserted-by":"crossref","first-page":"111437","DOI":"10.1016\/j.biopha.2021.111437","volume":"138","author":"JF Creeden","year":"2021","unstructured":"Creeden JF, Imami AS, Eby HM, Gillman C, Becker KN, Reigle J, et al. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection. Biomedicine Pharmacother. 2021;138:111437.","journal-title":"Biomedicine Pharmacother"},{"key":"1804_CR71","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(21)00232-7","volume":"8","author":"B Vai","year":"2021","unstructured":"Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021;8:797\u2013812. https:\/\/doi.org\/10.1016\/S2215-0366(21)00232-7.","journal-title":"Lancet Psychiatry"},{"key":"1804_CR72","doi-asserted-by":"publisher","unstructured":"Alegria M, Jackson JS, Kessler RC, Takeuchi D. Collaborative Psychiatric Epidemiology Surveys (CPES), 2001-3 [United States]: Version 7. 2007. https:\/\/doi.org\/10.3886\/ICPSR20240.V7.","DOI":"10.3886\/ICPSR20240.V7"},{"key":"1804_CR73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2021.21020196","volume":"179","author":"M S\u00e1nchez-Rico","year":"2022","unstructured":"S\u00e1nchez-Rico M, Limosin F, Hoertel N. Is a diagnosis of schizophrenia spectrum disorder associated with increased mortality in patients with COVID-19? AJP. 2022;179:71\u201373.","journal-title":"AJP"},{"key":"1804_CR74","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"1804_CR75","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Muela de la P, Abell\u00e1n M, Blanco C, Leboyer M, et al. Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: an observational multicenter study in France. Biol Psychiatry Glob Open Sci. 2022 Jan 4. https:\/\/doi.org\/10.1016\/j.bpsgos.2021.12.007.","DOI":"10.1016\/j.bpsgos.2021.12.007"},{"key":"1804_CR76","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/j.1360-0443.2011.03547.x","volume":"106","author":"Y Le Strat","year":"2011","unstructured":"Le Strat Y, Hoertel N. Correlation is no causation: gymnasium proliferation and the risk of obesity. Addiction. 2011;106:1871\u20132.","journal-title":"Addiction"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01804-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T14:12:11Z","timestamp":1669212731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01804-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1804"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-01804-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.22.21252209","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2021.02.18.21251997","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NH, MS-R., MA, PdlM, EG, JK, AC, and FL are inventors on a patent application related to methods of treating COVID-19, filled by Assistance Publique \u2013 Hopitaux de Paris in France. NH has received personal fees and non-financial support from Lundbeck, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}